MSC2156119J

DRUG2 trials

Sponsors

EMD Serono, Merck KGaA, Darmstadt, Germany

Conditions

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is AvailableSolid Tumors

Phase 1

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

CompletedNCT01014936

EMD SeronoPatients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Start: 2009-11-30End: 2015-10-31Updated: 2022-08-24

A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

CompletedNCT01832506

Merck KGaA, Darmstadt, GermanySolid Tumors

Start: 2013-04-30End: 2014-10-31Updated: 2020-08-06

Related Papers

Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called <i>MET</i> exon 14 skipping

Future Oncology2023-03-01

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.

2022-06-309 citations

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study

Cancer Medicine2021-09-097 citations

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

Japanese Journal of Clinical Oncology2020-03-2628 citations

Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).

Journal of Clinical Oncology2015-05-2011 citations

Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial

Cancer Research2014-10-011 citations

Abstract 2724: Development of a sensitive assay for measuring pharmacodynamic modulation of c-Met in biopsies

Cancer Research2014-10-01

Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2014-05-2011 citations